Company Overview and News

23
Saudi Arabia crisis shows Wall Street struggle between ethics and cash

6h financialexpress
As chief executive of the world’s biggest asset manager, Larry Fink began the year with a call to the thousands of companies that the firm holds stakes in: Show how they make a “positive contribution to society.” Now Fink’s BlackRock Inc., overseeing more than $6 trillion of other people’s money, is facing a comparable challenge, stuck between conscience and the implacable demands of the bottom line.
BGX DGLD BGLF CS HSB UGLD SCGLF MS HSBC HBCYF DSLV VIIX CSSLF VIIZ SCGLY BX HCS BGB 0005 CSGKF BLK HSEA CLNY HSEB ZIV USLV GLE TVIX XIV

3
Swiss banking secrecy dealt fresh setback in a month

2018-10-20 thestar.com.my
GENEVA: Two events this month may have finally brought the curtain down on Swiss banking secrecy rules.
JBARF DSLV VIIX DGLD CSSLF VIIZ HCS CS JBAXY HSB 0005 CSGKF UGLD HSEA HSEB ZIV USLV TVIX HSBC HBCYF XIV

 
HSBC revisits plan to list shares in China as London-Shanghai stock link looms

2018-10-19 scmp
HSBC Holdings has begun revisiting a plan to list its shares on the mainland, putting it on track to become first foreign company to issue depositary receipts on the mainland under the scheme that links the Shanghai and London stock exchanges.
HSB 0005 HSEA HSEB HCS HSBC HBCYF

17
PRESS DIGEST- British Business - Oct 19

2018-10-19 reuters
Oct 19 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
RDS.B RDS.A BNPQY RDSB SFTBF BNPQF RDSA HCS HSB 0005 BNPZY RYDBF HSEA HSEB 9984 RYDAF HSBC SFTBY DIS HBCYF

 
HSBC poised to be first firm to issue Chinese Depository Receipts: Sources

2018-10-18 moneycontrol
HSBC Holdings PLC is set to be the first company to issue Chinese Depository Receipts (CDRs), through a link between the London and Shanghai stock exchanges which will begin by year-end, people familiar with the matter told Reuters on Thursday.
STAN UL UNLYF ULVR UN HCS UNLNF HSB 0005 580001 STAB STAN STAC 2888 SCBFF HSEA HSEB HSBC HBCYF

 
China’s stocks fall to 4-year low amid fears of forced selling

2018-10-18 scmp
Benchmark gauge closes at lowest since November 2014 as fears grow that shares pledged as collateral will face forced sales, fuelling further losses
SCHYF WYNMF HSNGF HCS 0011 1128 HSB 0005 HSNGY HSEA 1928 HSEB SCHYY HSBC WYNMY HBCYF

 
Anglo-Gulf Trade Bank aims to bridge trade finance gap with blockchain

2018-10-17 channelnewsasia
ABU DHABI/LONDON: Anglo-Gulf Trade Bank, a British/UAE start-up, is aiming to shake up trade finance in the region by using blockchain to speed up transactions, becoming the latest financial services firm to adopt the technology.
STAN HCS HSB 0005 580001 STAB STAN STAC 2888 SCBFF HSEA HSEB HSBC HBCYF

20
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC

2018-10-11 zacks
Chicago, IL –October 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Altria (MO - Free Report) , U.S. Bancorp (USB - Free Report) ,Biogen (BIIB - Free Report) , Ecolab (ECL - Free Report) and HSBC Holdings (HSBC - Free Report) .
STZ.B STZ HCS USB HSB 0005 BIIB HSEA HSEB URBN HSBC ECL HBCYF

2
5 Bank Stocks That Pay Big Dividends to Shareholders

2018-10-11 investorplace
The banking sector — and bank stocks — saw an intriguing reversal in the 21st century.
WBC WEBNF WBK HCS HSB 0005 WBC HSEA NYCB HSEB HSBC ORIT BLX HBCYF

8
US trial begins for London forex traders accused of rigging prices

2018-10-11 malaymail
NEW YORK, Oct 11 — A US prosecutor yesterday urged jurors in Manhattan federal court to find three former London-based currency traders guilty of scheming to rig prices, kicking off the latest trial to emerge from a US probe into the multitrillion-dollar foreign exchange market.
BCS BNPQY HSB 83SF 83SK UBS HSBC HBCYF 47MC C BNPQF HCS 0005 BNPZY CGBBW HSEA HSEB ULSGF

5
Here's why the treasury drop is unlikely to spell doom for bunds

2018-10-10 thestar.com.my
LONDON: Investors inclined to sell treasuries without batting an eyelid are unlikely to repeat the feat on German bunds.
C HCS HSB 0005 CGBBW HSEA HSEB HSBC HBCYF

7
Top Analyst Reports for Altria, U.S. Bancorp & Biogen

2018-10-10 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), U.S. Bancorp (USB) and Biogen (BIIB). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LRCX HD LMT GD SCCO UTX HCS USB HSB 0005 BIIB HSEA HSEB HSBC ECL HBCYF

57
ConocoPhillips: 3 Factors That Will Fuel Earnings Growth

2018-10-09 seekingalpha
The price of the global benchmark Brent crude could climb to as high as $100 a barrel in the short term, which will greatly benefit ConocoPhillips.
COP BAC GS APC UBS TRI HSBC AEUA

2
UBS is accused in Paris tax-evasion trial of tactics akin to schemes in a Bond movie plot

2018-10-08 scmp
UBS Group AG goes on trial in Paris on Monday accused of encouraging rich clients to stash cash overseas to evade French taxes by deploying tactics “worthy of James Bond.”
HSB 0005 UBS HSEA HSEB HCS HSBC ULSGF HBCYF

19
5 Reasons to Add Capital One (COF) Stock to Your Portfolio

2018-10-05 zacks
Capital One (COF - Free Report) remains well positioned to grow, driven by consistent top-line rise, improving earnings performance and strong balance sheet position. Further, it has an impressive capital deployment plan. Yet, deteriorating asset quality and higher expense levels are major concerns for Capital One. Despite these headwinds, this Zacks Rank #2 (Buy) stock seems like an attractive investment opportunity right now as it has been witnessing solid upward estimate revisions.
GEC GE HCS YY HSB 0005 HSEA HSEB GNE HSBC HBCYF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to HSBC / HSBC Holdings Plc on message board site Silicon Investor.

HSBC (NYSE:HBC) a new era begins HSBC (NYSE:HBC) a new era begins HSBC (NYSE:HBC) a new era begins
CUSIP: 404280406